Tvardi Therapeutics to Participate in Upcoming Investor Events
Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharma company targeting STAT3 for inflammatory and proliferative diseases, will take part in two June 2026 investor events.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharma company targeting STAT3 for inflammatory and proliferative diseases, will take part in two June 2026 investor events.
Management will join fireside chats at the Jefferies Global Healthcare Conference and the Raymond James BioPharma CEO Strategy Series, with live webcasts and 90-day replays.
Details
News Market Reaction – TVRD
On May 21, the day this news came out, TVRD closed 6.75% below the previous close.
Data tracked by StockTitan Argus for the May 21 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:
Jefferies Global Healthcare Conference
Format: Fireside Chat and 1-on-1 Meetings
Date: Thursday, June 4, 2026
Time: 8:10 AM ET
Location: New York, NY
Raymond James BioPharma CEO Strategy Series
Format: Fireside Chat
Date: Friday, June 5, 2026
Time: 10:00 AM ET
Registration Link: Here
The webcasts of the Jefferies and Raymond James fireside chats will be accessible on the Tvardi Investors’ website. A replay of the webcasts will be available for approximately 90 days following the conference.
About Tvardi Therapeutics
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting clinical trials with TTI-109 in healthy volunteers and TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).
Contacts:
For Tvardi:
Tvardi Investor Relations
ir@tvardi.com
PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.